share_log

Novavax Shares Are Trading Higher After the Company Reported the Results From Its Phase 3 PREVENT-19 Trial Achieved Its Pre-specified Endpoint and the Results Form Its Study 307 Met Its Primary Endpoint.

Benzinga ·  Oct 12, 2022 15:24
Novavax shares are trading higher after the company reported the results from its Phase 3 PREVENT-19 trial achieved its pre-specified endpoint and the results form its Study 307 met its primary endpoint.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment